Business Wire

CA-GRINDR

20.11.2023 10:08:56 CET | Business Wire | Press release

Share
Grindr Brings Free At-Home HIV Self-Test Kits to Europe for the First Time With New Programs in Georgia and Ireland

At the outset of European testing week, Grindr Inc. (NYSE: GRND), the world’s largest social network for the LGBTQ+ community, today announced the launch of its new partnerships with Equality Movement and MPOWER to connect Grindr users directly with HIV self-test kits in Georgia and Ireland, respectively. With these partnerships, Georgia and Ireland become the first countries outside of the United States in which Grindr users can order free at-home HIV self-test kits directly from links embedded in the Grindr interface, in less than one minute.

Access to HIV testing continues to be one of the biggest obstacles in the fight against the global HIV epidemic. In-person testing, in particular, poses barriers such as clinic operating hours, transportation, costs, and concerns about privacy or stigma. These barriers become even more pronounced for a variety of Grindr users, such as those living in rural areas, or those who are not “out” to their families. At-home self-testing offers users a convenient and discrete option to protect their health.

Grindr has a long history of promoting both Equality Movement and MPOWER’s home self-testing programs. As it became clear that a significant number of Grindr users needed the level of flexibility and anonymity that home self-testing provides, Grindr decided to partner with both organizations to make this easier than ever. In expanding this collaboration, Grindr emphasizes both organizations’ commitment to implementing community-level interventions and judgment-free resources.

“For the past eight years, it has been my goal to find ways to increase access to HIV testing for Grindr users, and of all the things we’ve experimented with, embedding in-app links to home self-test kits has emerged as the most powerful strategy by a considerable margin,” said Jack Harrison-Quintana, Director of Grindr For Equality. “I could not be more excited to launch partnerships similar to those with Equality Movement and MPOWER around the world.”

“Making free at-home HIV self-testing available directly through the Grindr app helps to ensure members of the LGBTQ+ community have access to vital services they need to protect their health and feel supported in their daily lives,” said Lasha Nonikashvili at Equality Movement. “We are thrilled that the LGBTQ+ community across Georgia will now be able to protect their health with an easy solution they can access from home.”

“This partnership with Grindr has the potential to revolutionize the way our community across Ireland accesses vital at-home HIV self-testing,” said Adam Shanley at MPOWER, whose mission is to devise sex-positive, judgment-free and harm reduction-based resources, services and support for gay, bisexual and MSM in Ireland. “By making these resources more widely available at home, we hope to increase access, reduce stigma, and contribute to the long-term reduction of HIV.”

Today’s announcement builds on Grindr’s commitment to achieving a meaningful impact for the LGBTQ+ community. Earlier this year, we partnered with Building Healthy Online Communities and Emory University to launch Together TakeMeHome (TTMH) with support from the U.S. Centers for Disease Control and Prevention. TTMH is a unique partnership that has distributed over 232,262 test kits within the first six months of the program. Nearly a quarter of those orders were placed by people who had never previously tested for HIV, and a majority were requested through Grindr. Grindr remains committed to launching similar programs for users around the world.

About Grindr Inc.

With more than 13 million monthly active users in virtually every country in the world, Grindr has grown to become a fundamental part of the LGBTQ+ community since its launch in 2009. The company continues to expand its ecosystem to enable gay, bi, trans, and queer people to connect, express themselves, and discover the world around them. Grindr’s impact is further driven by Grindr for Equality’s wide-ranging initiatives that help the LGBTQ+ community around the world. Grindr is headquartered in West Hollywood, California. The Grindr app is available on the App Store and Google Play.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231120646279/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release

The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t

Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release

The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a

SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release

Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye